While monitoring cardiac function through imaging methods remains mandatory for HER2-positive breast cancer patients, cardiac damage without reflection in function changes should also be pondered; therefore, cardiac biomarkers should be carefully assessed. Here, ERBB2 is linked to breast carcinoma.